An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

NCT05562934 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Resistant Hypertension

Interventions

BIOLOGICAL: XXB750 drug
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals